Drugs / MIL95
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04651348 | Jan 2021 → Dec 2022 overdue | cancer | Beijing Mabworks Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIL95 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04651348 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Monoclonal Antibody MIL95” NCT04651348 ↗ |
| Route | Intravenous | “Each patient will receive an intravenous infusion of MIL95 every week” NCT04651348 ↗ |